Segev Barak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3900776/publications.pdf

Version: 2024-02-01

257450 254184 2,015 47 24 43 citations h-index g-index papers 51 51 51 2294 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol, 2014, 48, 243-252.	1.7	257
2	Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse. Nature Neuroscience, 2013, 16, 1111-1117.	14.8	165
3	Molecular mechanisms underlying alcohol-drinking behaviours. Nature Reviews Neuroscience, 2016, 17, 576-591.	10.2	156
4	Chromatin remodeling â€" a novel strategy to control excessive alcohol drinking. Translational Psychiatry, 2013, 3, e231-e231.	4.8	132
5	Corticostriatal BDNF and alcohol addiction. Brain Research, 2015, 1628, 60-67.	2.2	118
6	mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. Journal of Neurochemistry, 2014, 130, 172-184.	3.9	117
7	Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology, 2009, 202, 385-396.	3.1	74
8	Glial Cell Line-Derived Neurotrophic Factor Reverses Alcohol-Induced Allostasis of the Mesolimbic Dopaminergic System: Implications for Alcohol Reward and Seeking. Journal of Neuroscience, 2011, 31, 9885-9894.	3.6	74
9	Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia. Neuropsychopharmacology, 2009, 34, 1753-1763.	5.4	55
10	Counterconditioning During Reconsolidation Prevents Relapse of Cocaine Memories. Neuropsychopharmacology, 2017, 42, 716-726.	5.4	47
11	Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacology Biochemistry and Behavior, 2011, 99, 164-189.	2.9	46
12	AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology, 2011, 215, 149-163.	3.1	45
13	Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome. Behavioural Brain Research, 2009, 204, 335-351.	2.2	43
14	Scopolamine Induces Disruption of Latent Inhibition which is Prevented by Antipsychotic Drugs and an Acetylcholinesterase Inhibitor. Neuropsychopharmacology, 2007, 32, 989-999.	5.4	41
15	The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. International Journal of Neuropsychopharmacology, 2011, 14, 1233-1246.	2.1	41
16	Nucleus Accumbens-Derived Glial Cell Line-Derived Neurotrophic Factor Is a Retrograde Enhancer of Dopaminergic Tone in the Mesocorticolimbic System. Journal of Neuroscience, 2010, 30, 14502-14512.	3.6	39
17	SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacology Biochemistry and Behavior, 2012, 102, 203-214.	2.9	39
18	Advances in behavioral animal models of alcohol use disorder. Alcohol, 2019, 74, 73-82.	1.7	36

#	Article	IF	Citations
19	Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. International Journal of Neuropsychopharmacology, 2009, 12, 227.	2.1	34
20	<scp>GDNF</scp> is a novel ethanolâ€responsive gene in the <scp>VTA</scp> : implications for the development and persistence of excessive drinking. Addiction Biology, 2014, 19, 623-633.	2.6	32
21	Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS ONE, 2017, 12, e0188043.	2.5	32
22	Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption. Translational Psychiatry, 2011, 1, e60-e60.	4.8	31
23	Fibroblast Growth Factor 2 in the Dorsomedial Striatum Is a Novel Positive Regulator of Alcohol Consumption. Journal of Neuroscience, 2017, 37, 8742-8754.	3.6	30
24	Glial cell lineâ€derived neurotrophic factor <scp>(GDNF</scp>) is an endogenous protector in the mesolimbic system against excessive alcohol consumption and relapse. Addiction Biology, 2015, 20, 629-642.	2.6	28
25	Growth Factors and Alcohol Use Disorder. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a039271.	6.2	28
26	Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum. Journal of Neuroscience, 2019, 39, 7947-7957.	3.6	23
27	Lyn Kinase Regulates Mesolimbic Dopamine Release: Implication for Alcohol Reward. Journal of Neuroscience, 2011, 31, 2180-2187.	3.6	22
28	GDNF and alcohol use disorder. Addiction Biology, 2019, 24, 335-343.	2.6	22
29	The role of fibroblast growth factor 2 in drug addiction. European Journal of Neuroscience, 2019, 50, 2552-2561.	2.6	20
30	Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2013, 37, 8-15.	2.4	19
31	Re-exposure to nicotine-associated context from adolescence enhances alcohol intake in adulthood. Scientific Reports, 2017, 7, 2479.	3.3	18
32	Alcohol consumption alters Gdnf promoter methylation and expression in rats. Journal of Psychiatric Research, 2020, 121, 1-9.	3.1	17
33	Food-seeking behavior is triggered by skin ultraviolet exposure in males. Nature Metabolism, 2022, 4, 883-900.	11.9	17
34	Trophic factors as potential therapies for treatment of major mental disorders. Neuroscience Letters, 2021, 764, 136194.	2.1	16
35	Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice. Neuropsychopharmacology, 2019, 44, 415-424.	5. 4	15
36	Differential Role of Muscarinic Transmission within the Entorhinal Cortex and Basolateral Amygdala in the Processing of Irrelevant Stimuli. Neuropsychopharmacology, 2010, 35, 1073-1082.	5.4	13

#	Article	IF	CITATIONS
37	Memory Erasure, Enhanced Extinction and Disrupted Reconsolidation. Journal of Neuroscience, 2012, 32, 2250-2251.	3. 6	12
38	Flood-conditioned place aversion as a novel non-pharmacological aversive learning procedure in mice. Scientific Reports, 2018, 8, 7280.	3.3	10
39	Disruption of relapse to alcohol seeking by aversive counterconditioning following memory retrieval. Addiction Biology, 2021, 26, e12935.	2.6	9
40	Targeting the Reconsolidation of Licit Drug Memories to Prevent Relapse: Focus on Alcohol and Nicotine. International Journal of Molecular Sciences, 2021, 22, 4090.	4.1	9
41	FGF2 is an endogenous regulator of alcohol reward and consumption. Addiction Biology, 2022, 27, e13115.	2.6	9
42	Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology, 2010, 209, 175-184.	3.1	7
43	Counterconditioning following memory retrieval diminishes the reinstatement of appetitive memories in humans. Scientific Reports, 2019, 9, 9213.	3.3	7
44	Conversational Multitasking in Interactive Written Discourse as a Communication Competence. Communication Reports, 2006, 19 , $70-78$.	1.0	4
45	Effects of Visual Spatial Structure on Textual Conversational Multitasking. Communication Quarterly, 2009, 57, 104-115.	1.3	2
46	Choosing the Optimal Brain Target for Neuromodulation Therapies as Alcohol Addiction Progressesâ€"Insights From Pre-Clinical Studies. Current Addiction Reports, 2020, 7, 237-244.	3.4	1
47	Correction: Even-Chen et al., "Fibroblast Growth Factor 2 in the Dorsomedial Striatum Is a Novel Positive Regulator of Alcohol Consumption― Journal of Neuroscience, 2018, 38, 7754-7754.	3.6	O